Literature DB >> 25680571

YAP1-TFE3 epithelioid hemangioendothelioma: a case without vasoformation and a new transcript variant.

Florian Puls1, Angela Niblett, Jade Clarke, Lars-Gunnar Kindblom, Tom McCulloch.   

Abstract

Epithelioid hemangioendothelioma is a rare vascular tumor of borderline malignancy characterized by recurrent WWTR1-CAMTA1 gene fusions in approximately 90 % of cases. In addition, a recurrent YAP1-TFE3 gene fusion has been identified in WWTR1-CAMTA1 negative epithelioid hemangioendotheliomas. This subset has been reported as having a distinct morphology with more obvious vasoformation, voluminous eosinophilic cytoplasm, and TFE3 positivity on immunohistochemistry. We report a case of a YAP1-TFE3 translocated epithelioid hemangioendothelioma arising in a groin lymph node in a 29-year-old male. Plump spindle cell morphology and absence of vasoformation made correct diagnosis particularly difficult. Immunohistochemistry showed nuclear positivity for both ERG and TFE3, fluorescence in situ hybridization showed break apart for TFE3 and RT-PCR identified a YAP1 exon1 to TFE3 exon 6 transcript, a previously unreported fusion variant. Awareness of this solid morphology and variant fusion will aid in identification of future cases of this rare vascular tumor.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25680571     DOI: 10.1007/s00428-015-1730-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  24 in total

1.  Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins.

Authors:  M J Weterman; J J van Groningen; A Jansen; A G van Kessel
Journal:  Oncogene       Date:  2000-01-06       Impact factor: 9.867

2.  Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.

Authors:  P Argani; C R Antonescu; P B Illei; M Y Lui; C F Timmons; R Newbury; V E Reuter; A J Garvin; A R Perez-Atayde; J A Fletcher; J B Beckwith; J A Bridge; M Ladanyi
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  TFE3: a helix-loop-helix protein that activates transcription through the immunoglobulin enhancer muE3 motif.

Authors:  H Beckmann; L K Su; T Kadesch
Journal:  Genes Dev       Date:  1990-02       Impact factor: 11.361

Review 4.  The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease.

Authors:  Xaralabos Varelas
Journal:  Development       Date:  2014-04       Impact factor: 6.868

Review 5.  Malignant vascular tumors--an update.

Authors:  Cristina Antonescu
Journal:  Mod Pathol       Date:  2014-01       Impact factor: 7.842

6.  PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21).

Authors:  Pedram Argani; Cristina R Antonescu; Jérôme Couturier; Jean-Christophe Fournet; Raf Sciot; Maria Debiec-Rychter; Brian Hutchinson; Victor E Reuter; Lilliane Boccon-Gibod; Charles Timmons; Naiel Hafez; Marc Ladanyi
Journal:  Am J Surg Pathol       Date:  2002-12       Impact factor: 6.394

7.  Perivascular epithelioid cell tumor with SFPQ/PSF-TFE3 gene fusion in a patient with advanced neuroblastoma.

Authors:  Mio Tanaka; Keisuke Kato; Kiyoshi Gomi; Masae Matsumoto; Hironori Kudo; Masato Shinkai; Youkatsu Ohama; Hisato Kigasawa; Yukichi Tanaka
Journal:  Am J Surg Pathol       Date:  2009-09       Impact factor: 6.394

8.  A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23).

Authors:  Pedram Argani; Man Yee Lui; Jérôme Couturier; Raymonde Bouvier; Jean-Christophe Fournet; Marc Ladanyi
Journal:  Oncogene       Date:  2003-08-14       Impact factor: 9.867

9.  TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.

Authors:  Masumi Tsuda; Ian J Davis; Pedram Argani; Neerav Shukla; Gael G McGill; Makoto Nagai; Tsuyoshi Saito; Marick Laé; David E Fisher; Marc Ladanyi
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

10.  TGFBR3 and MGEA5 rearrangements in pleomorphic hyalinizing angiectatic tumors and the spectrum of related neoplasms.

Authors:  Jodi M Carter; William R Sukov; Elizabeth Montgomery; John R Goldblum; Steven D Billings; Karen J Fritchie; Andrew L Folpe
Journal:  Am J Surg Pathol       Date:  2014-09       Impact factor: 6.394

View more
  1 in total

Review 1.  Unraveling the Biology of Epithelioid Hemangioendothelioma, a TAZ-CAMTA1 Fusion Driven Sarcoma.

Authors:  Caleb N Seavey; Ajaybabu V Pobbati; Brian P Rubin
Journal:  Cancers (Basel)       Date:  2022-06-16       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.